Unicycive Therapeutics, Inc. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses), averaging -38.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.06 | not reported | not reported | |
| Q1 FY26 | $-0.55 | $-0.54 | +1.8% | Beat | |
| Q4 FY25 | $-0.46 | $-0.82 | -78.3% | Miss |
Back to UNCY overview · UNCY holders · UNCY KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.